Corrigendum to “Discovery of novel tetrahydroquinoline derivatives as potent, selective, and orally Available AR antagonists” [Eur. J. Med. Chem. 291 (2025) 117566]

IF 6 2区医学 Q1 CHEMISTRY, MEDICINAL

European Journal of Medicinal Chemistry Pub Date : 2025-05-03 DOI:10.1016/j.ejmech.2025.117707

Leer Yuan, Jianing Liao, Yiyang Qin, Lvtao Cai, Minkui Zhang, Jinbiao Liao, Dan Li, Tingjun Hou, Rong Sheng

引用次数: 0

Abstract

This note aims to correct an error in Table 1, Table 2, Tables 3 and 5.

1.In the version of this article initially published, there were several errors in Table 1.

查看原文本刊更多论文

“发现新型四氢喹啉衍生物作为有效的、选择性的、口服有效的AR拮抗剂”的勘误表[欧洲]。医学化学。291 (2025)117566]

本文旨在纠正表1、表2、表3和5.1中的一个错误。在本文最初发布的版本中，表1中有几个错误。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Medicinal Chemistry 化学-医药化学

CiteScore

11.70

自引率

9.00%

发文量

863

审稿时长

29 days

期刊介绍： The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.